


Dual therapy: MET+CANA vs. MET+SU HbA1c reductions over 104 weeks (LOCF)¹



*glimepiride titrated up to a maximum of 8mg once-daily.¹ The maximum licensed dose of glimepiride is 6mg.²

LS: Least-squares, CI: Confidence interval, SE: Standard error, LOCF: Last observation carried forward.

For canagliflozin 100mg, the upper limit of the 95% CI was less than the pre-specified non-inferiority margin of 0.3% compared with glimepiride. The upper limit of 95% CI for difference in HbA1c in canagliflozin 300mg vs glimepiride was <0.0%, demonstrating superiority of canagliflozin 300mg relative to glimepiride¹

Reference: 1. Cefalu WT et al. Poster presented at the 73rd Scientific Sessions of the ADA

2. AMARYL Summary of Product Characteristics, dated 17/10/2013 (last accessed August 2014).